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Key Points
Question
What is the effect of systematic depression screening with and without provision of enhanced depression
care on quality-adjusted life-years and depressive symptoms among survivors of acute coronary
syndromes?
Findings
In this randomized clinical trial that included 1500 survivors of acute coronary syndromes, there were no
differences in quality-adjusted life-years or depression-free days in those who were and were not screened
for depression, even when depression screening was followed by enhanced depression care.
Meaning
Contrary to recommendations from professional societies, systematic depression screening of survivors of
acute coronary syndromes may not be warranted.

Abstract
Importance
Patients with acute coronary syndrome (ACS) and elevated depressive symptoms are at increased risk for
recurrent cardiovascular events and mortality, worse quality of life, and higher health care costs. These
observational findings prompted multiple scientific panels to advise universal depression screening in
survivors of ACS prior to evidence from randomized screening trials.
Objective
To determine whether systematically screening for depression in survivors of ACS improves quality of life
and depression compared with usual care.
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Design, Setting, and Participants
A 3-group multisite randomized trial enrolled 1500 patients with ACS from 4 health care systems between
November 1, 2013, and March 31, 2017, with follow-up ending July 31, 2018. Patients were eligible if
they had been hospitalized for ACS in the previous 2 to 12 months and had no prior history of depression.
All analyses were performed on an intention-to-treat basis.
Interventions
Patients with ACS were randomly assigned 1:1:1 to receive (1) systematic depression screening using the
8-item Patient Health Questionnaire, with notification of primary care clinicians and provision of
centralized, patient-preference, stepped depression care for those with positive screening results (8-item
Patient Health Questionnaire score ≥10; screen, notify, and treat, n = 499); (2) systematic depression
screening, with notification of primary care clinicians for those with positive screening results (screen and
notify, n = 501); and (3) usual care (no screening, n = 500).
Main Outcomes and Measures
The primary outcome was change in quality-adjusted life-years. The secondary outcome was depressionfree days. Adverse effects and mortality were assessed by patient interview and hospital records.
Results
A total of 1500 patients (424 women and 1076 men; mean [SD] age, 65.9 [11.5] years) were randomized in
the 18-month trial. Only 71 of 1000 eligible survivors of ACS (7.1%) had elevated 8-item Patient Health
Questionnaire scores indicating depressive symptoms at screening. There were no differences in mean
(SD) change in quality-adjusted life-years (screen, notify and treat, –0.06 [0.20]; screen and notify, −0.06
[0.20]; no screen, −0.06 [0.18]; P = .98) or cumulative mean (SD) depression-free days (screen, notify and
treat, 343.1 [179.0] days; screen and notify, 351.3 [175.0] days; no screen, 339.0 [176.6] days; P = .63).
Harms including death, bleeding, or sleep difficulties did not differ among groups.
Conclusions and Relevance
In patients with ACS without a history of depression, systematic depression screening with or without
providing depression treatment did not alter quality-adjusted life-years, depression-free days, or harms.
Trial Registration
ClinicalTrials.gov identifier: NCT01993017

Introduction
Many patients with acute coronary syndromes (ACSs) experience clinically significant depressive
symptoms after the acute cardiac event,1,2 and approximately 10% of patients with ACS meet the criteria
for major depressive disorder.3 Depression in patients with ACS is associated with twice the risk of
mortality or recurrent cardiovascular events,4,5 lower quality of life,6 and greater health care costs.7 Citing
these observational data and the availability of effective depression treatments,3 multiple professional
societies have recommended depression screening in patients with ACS, followed by comprehensive
treatment when depression is detected.1,8,9,10,11,12
Controversy exists about recommendations to screen for depression in patients with ACS.13 Studies
demonstrating the effectiveness of depression treatment in patients with ACS have enrolled only patients
seeking treatment, limiting generalizability to patients whose depression is detected by screening. To our
knowledge, no depression screening trials have been conducted in patients with ACS.14 Some have argued
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6806435/?report=printable
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that until a randomized depression screening trial demonstrates improvements in depressive symptoms or
other outcomes, depression screening recommendations are premature.13,15 In the meantime, few
cardiologists or primary care providers (PCPs; physicians and nurse practitioners) have implemented
routine depression screening in patients with ACS.16,17 Primary reasons cited for delayed implementation
include lack of evidence from randomized screening trials and harms of screening.18,19 In addition to cost,
potential harms of depression screening include adverse psychological effects from depression labeling
and adverse biological effects related to increased use of antidepressant medications in those whose
screening results are positive.20,21,22
We report here on CODIACS-QoL (Comparison of Depression Interventions After Acute Coronary
Syndrome: Quality of Life), a depression screening trial of 1500 patients with ACS from 4 diverse health
care systems. Patients were randomized to 1 of 3 groups: (1) no depression screening, (2) screening and
notifying the PCP, and (3) screening, notifying the PCP, and providing enhanced depression treatment that
had previously been shown to be effective in patients with ACS, albeit not in a population that underwent
screening for depression.23,24 We sought to determine if depression screening after ACS improved qualityadjusted life-years (QALYs), and, secondarily, depressive symptoms and depression-free days.

Methods
Study Design and Setting
This multicenter randomized clinical trial had 3 groups: (1) systematic depression screening with
notification of PCPs and provision of patient-preference, stepped-care depression treatment for those with
positive screening results (screen, notify, and treat group); (2) systematic depression screening with
notification of PCPs only (screen and notify group); and (3) usual care (no screen group). Patients were
recruited from 4 geographically diverse health systems: HealthPartners (Minneapolis, Minnesota), Duke
University Health System (Durham, North Carolina), Kaiser Permanente Northwest (Portland, Oregon),
and New York–Presbyterian/Columbia University Irving Medical Center (New York, New York; recruiting
and coordinating site). Patients were screened for eligibility starting November 1, 2013, with enrollment
ending March 31, 2017, and 18-month follow-up ending July 31, 2018. The institutional review boards of
all 4 recruitment centers approved this study. Oral consent was obtained from all patients. Those who were
randomized to the screen, notify, and treat group were later asked to provide written consent. The trial
protocol and statistical analysis plans25 are available in Supplement 1.
Patients were eligible if they were age 21 years or older, spoke English or Spanish, and had documented
ACS within 2 to 12 months of enrollment based on standardized International Classification of Diseases,
Ninth Revision, or International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision, discharge codes for acute myocardial infarction and unstable angina.26 Eligibility was confirmed
via medical record review and baseline telephone interview. Patients were excluded if they were currently
receiving treatment for depression or had a prior history of depression; had a life expectancy less than 1
year; had a prior or current history of bipolar disorder, suicidal risk, or psychosis; had current substance
abuse; had dementia; were currently pregnant; had severe arthritis or rheumatologic illness; had advanced
liver disease requiring frequent hospitalizations; had advanced heart failure; had advanced lung disease
needing oxygen at home; had advanced HIV infection or AIDS; or had advanced cancer of any kind.
Patients were randomized in a 1:1:1 ratio to 1 of 3 groups, stratified by site. A web-based random number
generator integrated into the patient tracking system produced a blocked randomization assignment within
strata with randomly selected block sizes of 3, 6, or 9. Randomization assignment became visible to an
unblinded coordinator only after all baseline data had been entered. Concealment was ensured as group
allocation occurred in real time using the web-based computer algorithm. Unblinded coordinators then
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completed depression screening, notification, and referral to treatment if indicated by group assignment
and result of depression screening. Blinded coordinators conducted all outcome assessments while masked
to group allocation.
Intervention and Control Procedures
Patients assigned to the screen, notify, and treat group were screened for depression using the 8-item
Patient Health Questionnaire (PHQ-8), a research-grade, validated, sensitive, and specific depression
screening tool.27 Patients with clinically significant depressive symptoms (PHQ-8 score ≥10) had their
PCP and/or treating cardiologist notified of their elevated depressive symptoms via letter. Unblinded site
coordinators provided patients with education regarding depression treatment options and offered a freeof-charge 6-month course of patient preference–driven stepped-care depression treatment (problemsolving therapy, antidepressant, both, or none), which adhered to a previously published format and
algorithm.28 Depression treatment was provided without first requiring a clinical diagnosis of major
depression, as even subsyndromal symptoms of depression have been associated with risk of adverse
prognosis,29 and prior studies have verified the effectiveness of depression treatment in such patients.23,24
Intervention elements were delivered by a centralized, licensed clinical social worker with expertise in
telephone-delivered problem-solving therapy and/or a site psychiatrist, internist, or psychiatric nurse
practitioner with prescribing privileges.
Patients assigned to the screen and notify group were systematically screened for depression using the
PHQ-8, with notification of patients’ cardiologists and/or PCPs if a patient had positive screening results.
Subsequent depression treatment decisions were made by patients’ treating clinicians, and patients were
responsible for out-of-pocket costs of depression treatment.
Patients assigned to the no screen group were not systematically screened for depression using the PHQ-8.
Patients received usual care from their treating clinicians and were eligible to seek mental health screening
and/or treatments at their own expense.
Data Collection
After completing an eligibility questionnaire, eligible patients completed consent, baseline assessment, and
randomization by telephone. The assessment included age, sex, race, ethnicity, educational level, nativity
status, preferred language, partner status, employment status, health insurance coverage, the 10-item
Center for Epidemiologic Studies Depression scale (CESD-10), and a health-related quality-of-life
measure (the 12-Item Short-Form Health Survey, version 2).30 Follow-up data collection telephone calls
were conducted at 6, 12, and 18 months after baseline assessments. At these follow-up assessments,
patients completed the CESD-10; the 12-Item Short-Form Health Survey, version 2; a symptom checklist
assessing potential adverse consequences from depression screening and treatment; and items assessing
receipt of depression treatment since the prior study visit. At 18 months, patients also completed the PHQ8.
Outcomes
The prespecified primary outcome was change in QALYs from baseline through 18 months after
randomization. Utility scores, an overall assessment of well-being on a scale from 0 (death) to 1 (perfect
health), were estimated using the Short Form-6 dimension, with scores derived from responses to the 12Item Short-Form Health Survey, version 2, at baseline and 6, 12, and 18 months.31,32,33,34,35,36 Qualityadjusted life-years for the period from baseline to 18 months were calculated as the area under the curve by
linearly interpolating the utility scores at the 4 assessments. Change in QALYs was then obtained by
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subtracting the baseline QALY from the observed QALY for an 18-month period, where baseline QALY
was calculated under the assumption that the baseline utility score remained constant during the 18-month
period.
The prespecified secondary outcome was depression-free days based on the CESD-10, a nondiagnostic,
epidemiologic, reliable, and valid measurement for depressive symptoms.37 A CESD-10 score of 10 or
greater indicates elevated depressive symptoms.38 Depression-free days was calculated using linear
interpolation to estimate daily depression severity at each of the 4 assessments.
Additional outcomes included depressive symptoms as measured by the CESD-10 and the PHQ-8,
although the PHQ-8 was not assessed at baseline in the no screen group. Harms included potential adverse
effects from antidepressant medications (ie, appetite problems, sleep problems, gastrointestinal upset, and
bleeding) and mortality, assessed by surveying patient surrogates and through review of the electronic
medical record.
Statistical Analysis
Baseline characteristics were examined as means (SD) or percentages by randomization assignment to
assess for a balanced allocation. The primary comparison of change in QALYs among the 3 groups was
conducted using a 2-step gatekeeping test procedure. An omnibus F test using analysis of variance
comparing the 3 groups with one another was first performed, and pairwise comparisons using a 2-sided t
test at 5% nominal significance were planned only if the omnibus F test had a P value of less than .05.
This procedure would control the familywise type I error rate at 5%.39,40 In the secondary outcome
analysis, depression-free days of the 3 groups were compared using the same gatekeeping procedure.
All analyses used the principle of intention to treat. The missing patterns of QALYs, CESD-10 scores, and
PHQ-8 scores at each telephone follow-up were tested to see if they met the assumption of missing at
random using the Little test. As this assumption was met, missing data were handled using multiple
imputation, with the point estimate derived from the mean of 5 data sets and the pooled variance calculated
using the Rubin formula.41 Sensitivity analyses were performed using (1) worst outcome imputation and
(2) last observation carried forward. Sex-stratified analyses were also conducted for these outcomes.
Exploratory analyses of change in utility scores over time were performed in the framework of linear
mixed models with a random intercept to account for intrapatient correlation. These models included time
and randomization group as main effects and the time-by-group interaction.
Sample size was calculated to detect a clinically significant difference in change in QALYs. We
determined that a sample size per group of 500, assuming 5% loss to follow-up, would yield 80% power
for a 2-sided t test at the 5% level. These calculations were based on an assumed SD for QALYs of 0.17,42
expected prevalence of screening-detected depression of 20%, and assumed net improvement in QALYs of
0.155 over 18 months for individuals with depression who received treatment for depression in the screen,
notify, and treat group.43
Analyses were performed in R, version 3.4.3 (R Foundation for Statistical Computing). All P values were
from 2-sided tests, and results were deemed statistically significant at P < .05. Given the use of the 2-step
gatekeeping procedure, no adjustment for multiple comparisons was performed for the primary or
secondary outcomes.

Results
Participants
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There were 5332 patients identified as potentially eligible for depression screening after ACS based on
review of the electronic medical record, and 4039 patients were reached by telephone for assessment (
Figure 1). Of these patients, 2130 (52.7%) declined to participate in the study, and 1501 were ultimately
found to be eligible. One patient asked to have data withdrawn, such that the final sample size was 1500.
The mean (SD) age of patients was 65.9 (11.5) years; 424 were women, 1076 were men, and 244 were
Hispanic (Table 1). There were no substantial differences in demographic, depression, or health status
characteristics of patients in the 3 groups.
Among 499 patients randomized to the screen, notify, and treat group, 38 of 494 (7.7%) had positive
screening results for depression (ie, PHQ-8 score ≥10), and 28 of these patients with positive screening
results (73.7%) agreed to the patient-preference stepped-care intervention; 4 chose antidepressants, 14
chose problem-solving therapy, and 10 chose both. Of 501 patients randomized to the screen and notify
group, 33 (6.6%) had positive screening results for depression.
Change in QALYs
There were no significant differences in the change in mean (SD) QALYs between the 3 groups (screen,
notify, and treat, −0.06 [0.20]; screen and notify, −0.06 [0.20]; no screen, −0.06 [0.18]; P = .98) (Figure 2;
eTable 1 in Supplement 2). Quality-adjusted life-years declined modestly between baseline and 18 months
in all 3 groups. Results remained unchanged when conducting sensitivity analyses in which worst outcome
imputation and last observation carried forward were used to impute missing data. There were no
differences in outcomes when analyses were stratified by sex (eTable 2 in Supplement 2).
When examining utility scores derived from quality-of-life scores at all 4 time points, utilities gradually
declined from baseline to 18 months (Figure 2; eTable 1 in Supplement 2). A similar pattern was observed
in all 3 groups. Using a mixed model (secondary analysis), we found no differences in change in utility
scores from baseline to 18 months among the 3 groups.
Change in Depression-Free Days and Depressive Symptoms
There were no differences between the groups in cumulative mean (SD) depression-free days (screen,
notify, and treat, 343.1 [179.0] days; screen and notify, 351.3 [175.0] days; no screen, 339.0 [176.6] days;
P = .63) or change in CESD-10 depressive symptoms from baseline to 18 months (Figure 3). There were
also no differences in depressive symptoms as measured by the mean (SD) PHQ-8 score at 18 months
(screen, notify, and treat, 3.63 [4.40]; screen and notify, 3.60 [4.14]; no screen, 3.69 [4.21]; P = .99). There
were also no differences in depression-free days or depressive symptoms when analyses were stratified by
sex (eTable 2 in Supplement 2). At follow-up visits, there were no differences in the percentage of patients
who reported taking antidepressant medication or seeing a mental health clinician (eTable 3 in Supplement
2).
Harms of Depression Screening
There were no differences in mortality between the 3 groups, with 67 patients (4.5%) confirmed deceased (
Figure 1). There were also no differences in patient-reported harms potentially attributable to the use of
antidepressant medications (Table 2).

Discussion
In this 3-group, depression screening randomized clinical trial, we found no difference in change in
QALYs among patients with ACS who were randomized to depression screening and notification with or
without provision of enhanced depression care compared with a control group that did not undergo
depression screening. There was also no evidence for differences in depressive symptoms, depression-free
days, or patient-reported harms of screening among the 3 groups.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6806435/?report=printable
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There is compelling evidence that depression is a cardiotoxic risk marker in patients with ACS, strongly
and consistently associated with health-related quality of life, independent of traditional factors associated
with quality of life.44 For example, patients with a history of depression have twice the rate of angina,
triple the reported physical limitations, and almost triple the risk of diminished health-related quality of
life after ACS.45 Of multiple factors associated with 1-year quality of life in a study of patients with
myocardial infarction that included sociodemographic variables, severity of disease, and other factors,
depression was the most substantial factor.46 Despite the risk associated with depression, our data suggest
that a strategy of systematically screening patients with ACS for depression is unlikely to lead to
substantial population-level benefits in terms of improved quality of life or depression-free days.
There are several possible explanations as to why depression screening did not improve quality of life or
depressive symptoms. To begin with, a smaller than expected proportion of study patients had positive
screening results for depression. Our study intentionally excluded individuals with a history of depression,
even if they were not recently or currently being treated for depression. As depression is a relapsing and
remitting disorder that is often undertreated even when it is recognized, it is possible that expanding
depression assessments to encompass patients with ACS with a history of depression could case-find
additional patients with ACS who could benefit from enhanced depression treatment. Nearly 25% of those
who had positive screening results in the screen, notify, and treat group declined the enhanced depression
care treatment, which may have limited the potential for this screening approach to have an effect on
quality of life and depression. It is possible that, even among those who initiated depression treatment,
those who were identified as depressed by the screening may have been less motivated or interested in
treatment and, in turn, less engaged, limiting treatment effectiveness. Overall, by 6 months, there were no
differences in the percentage of patients in each group who had received depression treatment. Future
studies could investigate if motivation, interest, adherence, and/or engagement differ between patients with
depression detected by screening and patients with depression who are seeking treatment.
Currently, multiple professional societies recommend depression screening in patients with ACS. These
advisories are based on observational evidence that depression is prevalent for patient with ACS3 and is
associated with worse morbidity and mortality outcomes,4,46,47 worse quality-of-life outcomes,6 and
greater health care costs.7 Yet, evidence-based guidelines also rate the strength of evidence for clinical
recommendations, with the strongest recommendations reserved for meta-analyses of randomized clinical
trials. Our study provides a single, well-conducted randomized clinical trial that provides evidence against
depression screening in patients with ACS. Our findings suggest that existing guidelines advising routine
depression screening in patients with ACS may need to be reconsidered.
Our findings were consistent with recent research on the effect of depression screening in other contexts. A
cluster randomized clinical trial in England evaluated the effect of a point-of-care electronic prompt for
general practitioners to screen for depression, anxiety, and pain vs for pain alone among patients with
osteoarthritis.48 The electronic prompt did not result in lower depressive symptoms. From 2006 to 2013,
the United Kingdom Quality and Outcomes Framework financially incentivized systematic depression
screening of primary care patients with coronary heart disease or diabetes.49,50 It was estimated that 976
patients had to be screened for each new diagnosis of depression and 687 patients screened for each new
antidepressant prescription. Based on this low yield, depression screening was discontinued as a quality
indicator in the United Kingdom.
Strengths and Limitations
There were many strengths of our study, including successful accrual of patients across multiple health
care settings and representation of socioeconomically diverse patients with ACS in the sample. There were
also limitations. It is possible that patients assigned to the no screen group became more aware of
depressive symptoms through participation in the study, which, in turn, led to increased depression
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6806435/?report=printable
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recognition and treatment in this group. There have been public health efforts to increase screening for
depression in primary care settings, which may have led to smaller differences in depression screening
between the screened and no screen groups. Several patients with depression in the screen, notify, and treat
group declined the remotely delivered depression treatment provided by the study and reported pursuing
treatment from their usual care providers. It is possible that a higher proportion would have agreed to the
study depression treatment if it were better integrated into their usual clinical care.51 Nevertheless, given
the low prevalence of positive results of the depression screening and modest effectiveness of depression
treatments, better integration would be unlikely to substantially affect change in QALYs associated with
screen, notify, and treat. Approximately half of the patients approached declined to enroll in the study. The
applicability of this study to depression screening conducted outside the context of a trial may be different.

Conclusions
Providing universal depression screening and notifying treating clinicians of positive results of screening
either with or without provision of enhanced depression care did not substantially alter quality of life,
depression-free days, depressive symptoms, mortality, or patient-reported harms in patients with ACS.

Notes

Supplement 1.

Trial Protocol

Supplement 2.

eTable 1. Utility Scores and Depressive Symptoms from Baseline to 18 Months
eTable 2. Sex-Specific Analyses of Key Outcomes of CODIACS-QOL Trial
eTable 3. Patient-Reported Receipt of Mental Health Treatment Since the Prior Study Visit From 6
Months to 18 Months

Supplement 3.

Data Sharing Statement
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Figure 1.

CONSORT Flowchart
PST indicates problem-solving therapy.
a

From the Screen, Notify, and Treat group.
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Table 1.
Baseline Characteristicsa
Characteristic

Overall (N

Screen, Notify, and Treat

Screen and Notify

No Screen

= 1500)

Group (n = 499)

Group (n = 501)

Group (n = 500)

Age, mean (SD), y

65.9 (11.5)

66.2 (11.3)

65.8 (11.7)

65.8 (11.7)

Male sex

1076 (71.7)

357 (71.5)

364 (72.7)

355 (71.0)

White

1080 (72.0)

353 (70.7)

368 (73.5)

359 (71.8)

Black

130 (8.7)

47 (9.4)

37 (7.4)

46 (9.2)

Other

259 (17.3)

92 (18.4)

82 (16.4)

85 (17.0)

Refused or unknown

31 (2.1)

7 (1.4)

14 (2.8)

10 (2.0)

Hispanic

244 (16.3)

82 (16.4)

88 (17.6)

74 (14.8)

Non-Hispanic

1218 (81.2)

406 (81.4)

402 (80.2)

410 (82.0)

Refused or unknown

38 (2.5)

11 (2.2)

11 (2.2)

16 (3.2)

Born in the United

1169 (77.9)

392 (78.6)

392 (78.2)

385 (77.0)

English as first

1282/1495

426/497 (85.7)

427/501 (85.2)

429/497 (86.3)

language

(85.8)

191/493 (38.7)

178/498 (35.7)

167/496 (33.7)

105/493 (21.3)

119/498 (23.9)

112/496 (22.6)

197/493 (40.0)

201/498 (40.4)

217/496 (43.8)

318/495 (64.2)

336/498 (67.5)

312/496 (62.9)

205/492 (41.7)

198/500 (39.6)

203/496 (40.9)

475/496 (95.8)

482/499 (96.6)

475/496 (95.8)

38/494 (7.7)

33/501 (6.6)

NA

Race

Ethnicity

States

Educational level,
No./total No. (%)
High school or lower

536/1487
(36.0)

Some college

336/1487
(22.6)

College and higher

615/1487
(41.4)

Married

966/1489
(64.9)

Employed

606/1488
(40.7)

Covered by health

1432/1491

insurance

(96.0)

PHQ-8 score ≥10

NA

Abbreviations: CESD-10, 10-item Center for Epidemiologic Studies Depression Scale; NA, not applicable; PHQ-8,
8-item Patient Health Questionnaire; SF-12, 12-Item Short-Form Health Survey.
a

Data are presented as number (percentage) of patients unless otherwise specified. Less than 1% of data are missing
for some categorical variables such that totals may add up to less than 100%.
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Figure 2.

Quality-of-Life Utility Score and Change in Quality-Adjusted Life-Years (QALYs) From Baseline to 18 Months
Error bars indicate SD.
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Figure 3.

Depression-Free Days and Depressive Symptoms From Baseline to 18 Months
Error bars indicate SD. CESD indicates 10-item Center for Epidemiologic Studies Depression scale.
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Table 2.
Harms Associated With Depression Screening From 6 to 18 Months
Outcome

Patients, No./Total No. (%)
At 6 mo

At 12 mo

Screen,

Screen

Notify,

and

and

Notify

Control P

Value Notify,
and

Treat
Any bleeding

Screen,

At 18 mo
Screen

Control P

and

Value Notify,

Notify

and

Treat

Screen

C

and
Notify

Treat

61/450

51/455

72/457

(13.6)

(11.2)

(15.8)

Increased

83/450

84/455

91/457

appetite

(18.4)

(18.5)

(19.9)

Decreased

72/450

74/455

76/457

appetite

(16.0)

(16.3)

(16.6)

Drowsiness

218/450 212/455 217/458 .86

179/423 187/431 198/427 .47

152/394 177/410 1

(48.4)

(42.3)

(43.4)

(46.4)

(38.6)

(43.2)

(

Gastrointestinal 128/450 116/454 112/457 .38

95/423

95/431

107/427 .53

98/394

99/410

1

upset

(22.5)

(22.0)

(25.1)

(24.9)

(24.1)

(

(28.4)

(46.6)
(25.6)

.13

Screen,

.81
.97

(47.4)
(24.5)

51/423

50/429

50/427

(12.1)

(11.7)

(11.7)

71/423

77/431

76/427

(16.8)

(17.9)

(17.8)

63/423

65/431

76/427

(14.9)

(15.1)

(17.8)
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.98
.90
.43

40/394

45/410

4

(10.2)

(11.0)

(

76/394

62/410

6

(19.3)

(15.1)

(

53/394

45/410

6

(13.5)

(11.0)

(
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